Background: Psychosis spectrum disorders, especially schizophrenia, have been linked to disturbed dopaminergic activity in the brain. Plasma homovanillic acid (pHVA) levels partly represent dopaminergic metabolism in the central nervous system. In the present study associations between (changes in) pHVA levels, symptom severity and symptomatic improvement in patients with psychoses were investigated. Methods: From a total of 80 patients, 58 fulfilled all inclusion criteria and their symptom profile and severity were assessed by means of the Comprehensive Assessment of Symptoms and History (CASH), the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression Scale for Severity and Improvement (CGI-S/CGI-I) at baseline and after 6 weeks of antipsychotic treatment. After inclusion, all patients were prescribed first- or second-generation antipsychotics by their treating psychiatrist. A total of 12 patients had first-episode psychosis (FEP). At both time points, pHVA levels were measured. Subsequently, pHVA levels were compared with an age-matched control sample and changes in pHVA levels (ΔpHVA) after treatment were associated with clinical parameters. Results: Before analyses, data were scrutinized for possible confounders, particularly gender, smoking, medication status (including antipsychotic class), and recent drug use. The pHVA levels in patients were not different from those in controls. Treatment resulted in a significant decrease of all parameters. Symptomatic improvement as well as ΔpHVA was most pronounced in FEP patients. Conclusion: These findings show that patients with FEP have a more favourable outcome than non-FEP patients and that greater ΔpHVA also suggests that FEP patients still have the capacity to adjust dopaminergic neurotransmission.

Keywords:
Psychosis, First-episode psychosis, Dopamine, Homovanillic acid, Treatment responsiveness
1.
Kapur S, Mizrahi R, Li M: From dopamine to salience to psychosis - linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 2005;79:59-68.
2.
Howes OD, Kapur S: The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr Bull 2009;35:549-562.
3.
Lau CI, Wang HC, Hsu JL, Liu ME: Does the dopamine hypothesis explain schizophrenia? Rev Neurosci 2013;24:389-400.
4.
Amin F, Davidson M, Kahn RS, Schmeidler J, Stern R, Knott PJ, Apter S: Assessment of the central dopaminergic index of plasma HVA in schizophrenia. Schizophr Bull 1995;21:53-66.
5.
Pickar D, Labarca R, Doran AR, Wolkowitz OM, Roy A, Breier A, Linnoila M, Paul SM: Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Arch Gen Psychiatry 1986;43:669-676.
6.
Sumiyoshi T, Hasegawa M, Jayathilake K, Meltzer HY: Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance. Biol Psychiatry 1997;41:560-566.
7.
Oades RD, Klimke A, Henning U, Rao M: Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia. Hum Psychopharmacol Clin Exp 2002;17:15-27.
8.
Thibaut F, Ribeyre JM, Dourmap N, Ménard JF, Dollfus S, Petit M: Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia. Biol Psychiatry 1998;43:24-30.
9.
Baeza I, Castro-Fornieles J, Deulofeu R, De la Serna E, Goti J, Salvà J, Bernardo M: Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients. Psychiatry Res 2009;168:110-118.
10.
Suzuki E, Kanba S, Nibuya M, Adachi S, Sekiya U, Shintani F, Kinoshita N, Yagi G, Asai M: Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients. Biol Psychiatry 1994;36:654-661.
11.
Sumiyoshi T, Kurachi M, Kurokawa K, Yotsutsuji T, Uehara T, Itoh H, Saitoh O: Plasma homovanillic acid in the prodromal phase of schizophrenia. Biol Psychiatry 2000;47:428-433.
12.
Zumárraga M, Dávila R, González-Torres MA, Anguiano JB, Zabalo MJ, Basterreche N, Arrué A, Zamalloa MI, Guimón J: Inter- and intra-individual variability in the levels of plasma homovanillic acid in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:713-719.
13.
Kaneda Y, Kawamura I, Ohmori T: Correlation between plasma homovanillic acid levels and the response to atypical antipsychotics in male patients with schizophrenia. Clin Neuropharmacol 2005;28:262-264.
14.
Garver DL, Steinberg JL, McDermott BE, Yao JK, Ramberg JE, Lewis S, Kingsbury SJ: Etiologic heterogeneity of the psychoses: is there a dopamine psychosis? Neuropsychopharmacology 1997;16:191-201.
15.
Yoshimura R, Ueda N, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J: Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J Biol Psychiatry 2010;11:256-261.
16.
Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Katsuki A, Hayashi K, Atake K, Tomita M, Nakamura J: Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients. Hum Psychopharmacol Clin Exp 2012;27:33-38.
17.
Davidson M, Kahn RS, Stern RG, Hirschowitz J, Apter S, Knott P, Davis KL: Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res 1993;46:151-163.
18.
Davila R, Gonzalez MA, Zumarraga M, Andia I, Guimon J, Silva RR, Friedhoff AJ: Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia. Biol Psychiatry 1995;38:267-269.
19.
Scheepers FE, Gispen-de Wied CC, Westenberg HGM, Kahn RS: The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology 2001;25:468-475.
20.
Galinowski A, Castelnau C, Spreux-Varoquaux O, Bourdel MC, Olie JP, Loo H, Poirier MF: Evolution of plasma homovanillic acid (HVA) levels during treatment in schizo-affective disorder. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:1319-1328.
21.
Zumárraga M, Dávila R, Basterreche N, Arrué A, Goienetxea B, González-Torres MA, Guimón J: Plasma homovanillic acid and family history of psychotic disorders in bipolar I patients. Pharmacol Res 2009;59:269-272.
22.
Morimoto K, Miyatake R, Nakamura M, Watanabe T, Hirao T, Suwaki H: Delusional disorder: molecular genetic evidence for dopamine psychosis. Neuropsychopharmacology 2002;26:794-801.
23.
Andreasen NC, Flaum MC, Arndt S: The comprehensive assessment of symptoms and history (CASH): an instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 1992;49:615-623.
24.
Kay SR, Fiszbein A, Opfer LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
25.
Guy W: ECDEU Assessment Manual for Psychopharmacology, revised. Bethesda, National Institute of Mental Health, 1976.
26.
Fleischhacker W, Kemmler G: The clinical relevance of percentage improvements on the PANSS score. Neuropsychopharmacology 2007;32:2435-2436.
27.
Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR: Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441-449.
28.
Soda E, Miura I, Hoshino H, Kanno-Nozaki K, Ota T, Oguchi H, Watanabe K, Yang Q, Mashiko H, Niwa SI: Impacts of age on plasma monoamine metabolite concentrations in a large cohort of healthy individuals. Psychiatry Res 2014;220:639-645.
29.
Tuckwell HC, Koziol JA: A meta-analysis of homovanillic acid concentrations in schizophrenia. Int J Neurosci 1993;73:109-114.
30.
Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA: Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544-549.
31.
Yoshimura R, Ueda N, Shinkai K, Nakamura J: Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. Int Clin Psychopharmacol 2003;18:107-111.
32.
Nagaoka S, Iwamoto N, Arai H: First-episode neuroleptic-free schizophrenia: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment. Biol Psychiatry 1997;41:857-864.
33.
Beuger M, Van Kammen DP, Kelley ME, Yao J: Dopamine turnover in schizophrenia before and after haloperidol withdrawal. Neuropsychopharmacology 1996;15:75-86.
34.
Kelley ME, Yao JK, Van Kammen D: Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in schizophrenia. Neuropsychopharmacology 1999;20:603-611.
35.
Zumárraga M, González-Torres MA, Arrué A, Dávila R, Dávila W, Inchausti L, Pérez-Cabeza L, Fernández-Rivas A, Bustamante S, Basterreche N, Guimón J: Variability of plasma homovanillic acid over 13 months in patients with schizophrenia; relationship with the clinical response and the Wisconsin card sort test. Neurochem Res 2011;36:1336-1343.
36.
Garver DL, Holcomb JA, Christensen JD: Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. J Clin Psychiatry 2000;61:964-972.
37.
Mazure CM, Bowers MB: Pretreatment plasma HVA predicts neuroleptic response in manic psychosis. J Affect Disord 1998;48:83-86.
38.
Green AI, Tsuang MT, Schildkraut JJ: Catecholamines, their metabolites, and responses to typical and atypical neuroleptics: toward an understanding of the mechanisms of action of neuroleptic drugs; in Friedhoff AJ, Amin F (eds): Plasma Homovanillic Acid in Schizophrenia. Washington, American Psychiatric Press, 1997.
39.
Nishimura J, Kakeda S, Abe O, Yoshimura R, Watanabe K, Goto N, Hori H, Sato T, Takao H, Kabasawa H, Nakamura J, Korogi Y: Plasma levels of 3-methoxy-4-hydroxyphenylglycol are associated with microstructural changes within the cerebellum in the early stage of first-episode schizophrenia: a longitudinal VBM study. Neuropsychiatr Dis Treat 2014;10:2315-2323.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.